Diaceutics (DXRX) CME 2024 summary

Strategic direction, business model, and assets

• Transitioned from consulting to a high-margin, recurring revenue model with a three-year revenue CAGR of 23% and strong order book visibility out to 2026, aiming for profitability in 2025.

• Operates a proprietary global lab network of nearly 1,000 labs, the world's largest healthcare data repository, and the DXRX platform for precision medicine commercialization.

• Focused on expanding enterprise-wide deals, executing a land-and-expand strategy, and scaling commercial operations and product development.

• Enhanced commercial structure with account teams, business partners, and business development managers to deepen relationships and drive cross-sell/upsell opportunities.

• Fully self-funded to execute growth plans, with enterprise-wide deals and M&A/partnering opportunities expected to drive further momentum.

Data platform, technology, and product innovation

• Built a proprietary global lab network providing daily, de-identified patient-level data, with advanced AI and NLP for data cleaning and integration.

• DXRX platform delivers daily, actionable insights to 17 of the top 20 pharma companies, enabling hyper-targeted physician engagement and rapid clinical trial recruitment.

• Over 1.8 billion rows of lab data, covering more than 67,000 test types and 23 million patient lives, growing by 8 million annually.

• Data strategy emphasizes patient-level tokenization, linking diverse datasets (lab, EHR, claims, Rx) for a 360-degree patient view, supporting expansion beyond oncology.

• AI and automation have enabled a shift from weekly to daily data feeds, increasing the value and timeliness of insights for clients.

Market opportunity, partnerships, and competitive positioning

• Addressable market is significantly larger than current penetration, with opportunities to grow revenue per brand from £380k to £2–3m annually through cross-sell, upsell, and new product adoption.

• Strategic alliance with KPMG leverages complementary expertise to deliver transformational solutions across the precision medicine ecosystem.

• Recognized as a leader in lab data and precision medicine, with a differentiated offering that combines global data aggregation, advanced analytics, and deep industry relationships.

• Expansion plans include targeting non-oncology indications and non-pharma clients, leveraging learnings from oncology to address larger, more complex populations.

• Competitive landscape includes labs and claims/EHR data providers, but no direct competitor matches the breadth, integration, and precision medicine focus.